Orphazyme's Arimoclomol Disappoints For Muscle-Wasting Disorder
Pivotal Trial Failure For ‘Pipeline-In-A-Product’
The Danish biotech's stock sank after arimoclomol failed in a Phase II/III trial for inclusion body myositis. Orphazyme is hoping for much better news in the coming weeks as the US FDA makes its decision on the drug as a treatment for Niemann-Pick disease Type C.
